Siemens Healthineers reported fourth-quarter revenue of €6.78 billion, up 7.3% year over year, with comparable growth of 5.9% exceeding analyst expectations. Imaging led with 10% comparable growth, while Precision Therapy rose 4.8% and Diagnostics declined 4.2%; adjusted EBIT fell 2% and its margin narrowed to 15.9%, though net profit edged higher. For fiscal 2027, the company forecast comparable revenue growth of 4% to 5% and adjusted earnings per share of €2.20 to €2.40, both below analyst estimates and with the earnings range below fiscal 2026’s €2.42. Siemens Healthineers cited inflation, tax-rate normalization and separation costs among the earnings headwinds; strong order momentum was reflected in a book-to-bill ratio of 1.15.
Where do you stand?
How it spread
What each side asserts, disputes — or leaves out entirely.
Whose framing of this story rings truest to you?
Expecting just 4 to 5 percent growth feels overly cautious when the imaging business is still expanding.
Siemens Healthineers should focus harder on cutting costs since margins dropped despite the sales increase.
The revenue growth looks decent but falling profits and that weak 2027 forecast will hurt investor confidence.